

Ad hoc disclosure



Ad hoc disclosure according to Art. 17 of the European Market Abuse Directive

- CytoTools AG: Management and Supervisory Boards approve a capital increase -

Darmstadt, 9th November 2018 – With the approval of the Supervisory Board, today, the Management Board of the CytoTools AG (WKN: A0KFRJ; ISIN: DE000A0KFRJ1), passed a resolution to increase the share capital of the company from EUR 2,120,252.00 by EUR 212,000.00 to EUR 2,332,252.00. The capital increase takes place by cash deposit, excluding the right of subscription of the shareholders, at a placement price of EUR 7.00 per share. The gross proceeds of EUR 1,484,000.00 from the issue are to be used in particular to partially underpin, at an early stage, the planned clinical phase III trials with DermaPro® for the coming year. The new shares, with entitlement to dividends from 1st January 2018, were subscribed by a German institutional investor, who, among other projects, also invests in further domestic issuers in the biotechnology field.

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

End of the ad hoc disclosure

About CytoTools

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (59%) and CytoPharma GmbH (50 %).